CLLS · Cellectis ADR
United States · RS rating 3 · As of 2026-10-14
| Price | 1.12 USD |
|---|---|
| 1-day change | +1.8% |
| RS rating (overall / 1M / 3M / 12M) | 3 / 6 / 4 / 8 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 5 / 34 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +30.8% |
| Sales growth Q/Q | -70.4% |
| Distance from 52-week high | +79.1% |
| Market cap (USD) | $393.3M |